Probatebeta
Target

MTOR

Serine/threonine-protein kinase mTOR

As of the edition of 20 October 2026, MTOR (serine/threonine-protein kinase mTOR, UniProt P42345) has 29 drugs tested at it and 32 companies on the list, 22 on route A and 1 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P42345
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
74
Disease areas
Cancer; Skin and connective tissue; Urinary and reproductive; Blood and lymph; Pregnancy and women's health; Immune system; Lungs and airways; Nervous system
Registered trials of its drugs
287

Drugs at this target

StatusCount
Marketed1
Active2
Went quiet9
Stopped15
Withdrawn from market1
Status not established1
Total29
DrugStatusFurthest phaseUS protection
SapanisertibActivePhase 2none listed
RidaforolimusStoppedPhase 3none listed
VistusertibStoppedPhase 2none listed
DactolisibWent quietPhase 3none listed
GedatolisibMarketedPhase 3Ends 2031
SamotolisibStoppedPhase 2none listed
IndoximodStoppedPhase 2none listed
ApitolisibActivePhase 2none listed
VoxtalisibWent quietPhase 2none listed
BimiralisibStoppedPhase 2none listed
OnatasertibStoppedPhase 2none listed
PerhexilineWithdrawn from marketPhase 3none listed

12 of 29 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A22
Route B1
Engaged4
Undetermined5
Total on the list32
Three companies on route A or B, with the route only
CompanyRoute
Merck & Co.Route A
NovartisRoute A
Eli LillyRoute A

The other 29 companies at MTOR

In the product

32 companies in all; 29 are not named here, and no score is.

See the 32 companies at MTOR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at MTOR

Other targets in cancer